Results 51 to 60 of about 2,411,456 (284)

Inhibition of dipeptidyl peptidase 7 impairs lysophagy in LLOMe‐treated HepG2 cells

FEBS Letters, EarlyView.
DPP7 inhibition delays ubiquitin‐dependent lysophagy by attenuating ubiquitin accumulation and the recruitment of SQSTM1 and LC3 to damaged lysosomes, resulting in delayed clearance of damaged lysosomes and impaired restoration of lysosomal homeostasis. Created using FigureLabs (Certificate ID: FL‐PUB‐20260922‐Z99XNX).
Na Yeon Park, Inho Kwon, Yong Hwan Kim, Ji‐Eun Bae, Joon Bum Kim, Seong Hyun Kim, Sungho Maeng, Doo Sin Jo, Dong‐Hyung Cho   +8 more
wiley   +1 more source

NIH Workshop on Trustworthy Data Repositories for Biomedical Sciences

, 2019
The NIH Data Science Strategic Plan aims to modernize the ecosystem of biomedical data repositories. This workshop introduced the concepts of trust principles for data repositories, which address management aspects of data repositories. The workshop also
NIH ODSS Data Science Strategic Plan Implementation Subgroup 2.1.3&2.1.6 (7301067)
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer

Molecular Oncology, EarlyView.
Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola, Yasmine Illi, Anna Bircher, Marijn Wilmink, Rachele F. Malagutti, Solenn Ottié, Cordelia Schuler, Pedro A. Ruiz, Cheryl de Vallière, Klaus Seuwen, Gerhard Rogler, Martin Hausmann   +11 more
wiley   +1 more source

Key Role of alpha-Toxin in Fatal Pneumonia Caused by Staphylococcus aureus Sequence Type 398

, 2016
Intramural NIH HHSNIAID NIH HHSNIH, Bethesda, MD 20892 USAUniv Estadual Paulista, Botucatu, SP, BrazilUniv Estadual Paulista, Botucatu, SP, BrazilNIAID NIH HHS: ZIA ...
Bonesso, Mariana F. [UNESP], Otto, Michael, Yeh, Anthony J., Cunha, Maria L. R. S. [UNESP], McCausland, Joshua, Sobrinho, Moises T. [UNESP], Ronchi, Carlos F. [UNESP], Villaruz, Amer E., Cheung, Gordon Y. C., Joo, Hwang-Soo, Fortaleza, Carlos M. C. B. [UNESP], Cavalcante, Ricardo S. [UNESP]   +11 more
core   +1 more source

Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin

OncoImmunology, 2018
A major advantage of immunotherapy of cancer is that effector cells induced at one site should be able to kill metastatic cancer cells in other sites or tissues.
Jessica J. O'Konek, Elena Ambrosino, Anja C. Bloom, Lise Pasquet, Chandirasegaran Massilamany, Zheng Xia, Masaki Terabe, Jay A. Berzofsky   +7 more
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

478 Rigor and reproducibility activities across the CTSA consortium: A retrospective review of accomplishments

Journal of Clinical and Translational Science
Objectives/Goals: To assess how rigor and reproducibility activities across the Clinical and Translational Science Awards (CTSA) consortium are aligned with NCATS Translational Science Principles (TSPs) and the NIH’s new plan to promote gold standard ...
Francisco Leyva, Gallya Gannot, Monica Donerson, Andrew Vaught, Katherine Patel, Soju Chang   +5 more
doaj   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source